Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage

Kidney International

Volumn 68, Issue 5, 2005, Pages 2131-2142

  Rodríguez Iturbe, Bernardo ^a   Ferrebuz, Atilio ^b   Vanegas, Valentina ^b   Quiroz, Yasmir ^b   Espinoza, Fabiana ^b   Pons, Hector ^b   Vaziri, Nosratola D ^b  

^a HOSPITAL UNIVERSITARIO DE MARACAIBO   (Venezuela)

^b NONE

Author keywords

Chronic renal disease; Hypertension; Inflammation; Lymphocytes; Macrophages; Phosphodiesterase 5 inhibition; Sildenafil

Indexed keywords

CYCLIC GMP PHOSPHODIESTERASE; LOSARTAN; PHOSPHODIESTERASE INHIBITOR; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; CAPILLARY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE COURSE; ENZYME INHIBITION; EXPERIMENTATION; GLOMERULOSCLEROSIS; HISTOLOGY; HYPERTENSION; INFLAMMATION; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY SURGERY; MALE; NEPHRECTOMY; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA; RAT; THERAPY DELAY; UREMIA;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; APOPTOSIS; BLOOD PRESSURE; CYCLIC GMP; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; KIDNEY FUNCTION TESTS; MALE; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC;

EID: 30944437637     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00669.x     Document Type: Conference Paper

References (48)

1. BRENNER BM, MEYER TW, HOSTETTER TH: Dietary protein intake and the progressive nature of kidney disease: The role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging, renal ablation, and intrinsic renal disease. N Engl J Med 307:652-659, 1982
2. RODRÍGUEZ-ITURBE B, PONS H, HERRERA-ACOSTA J, JOHNSON RJ: The role of immunocompetent cells in non-immune renal diseases. Kidney Int 59:1626-1640, 2001
3. ROCZNIAK A, FRYER JN, LEVINE DZ, BURNS KD: Downregulation of neuronal nitric oxide synthase in the rat remnant kidney. J Am Soc Nephrol 10:704-713, 1999
4. VAZIRI ND, NI Z, WANG XQ, et al: Downregulation of nitric oxide synthase in chronic renal insufficiency: Role of excess PTH. Am J Physiol Renal Physiol 274:F642-F649, 1998
5. SCHMIDT RJ, BAYLISS C: Total nitric oxide production is low in patients with chronic renal disease. Kidney Int 58:1261-1266, 2000
6. VALLANCE P, LEONE A, CALVER A, et al: Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575, 1992
7. VAZIRI ND: Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 13:93-99, 2004
8. HIMMELFARB J, STENVINKEL P, IKIZLER TA, HAKIM RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 62:1524-1538, 2002
9. ROMERO F, RODRIGUEZ-ITURBE B, PARRA G, et al: Mycophenolate prevents the progressive renal failure induced by 5/6 renal ablation in rats. Kidney Int 55:945-955, 1999
10. ALVAREZ V, QUIROZ Y, NAVA M, RODRIGUEZ-ITURBE B: Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 283:F1132-F1141, 2002
11. QUIROZ Y, PONS H, GORDON KL, et al: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from nitric oxide synthesis inhibition. Am J Physiol Renal Physiol 281:F38-F47, 2001
12. RODRIGUEZ-ITURBE B, PONS H, QUIROZ Y, et al: Mycophenolate mofetil prevents salt-sensitive hypertension resulting from angiotensin II exposure. Kidney Int 59:2222-2232, 2001
13. RAIJ L, AZAR S, KEANE W: Mesangial immune injury, hypertension and progressive damage in Dahl rats. Kidney Int 26:137-143, 1984
14. RODRIGUEZ-ITURBE B, QUIROZ Y, NAVA M, et al: Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 282:F191-F201, 2002
15. PARRA G, HERNANDEZ S, MORENO P, RODRIGUEZ-ITURBE B: Participation of tubulointerstitium in acute immune-complex nephritis: Interstitial antigen accumulation, cellular infiltrate and MHC class II expression. Clin Exp Immunol 133:44-49, 2003
16. QUIROZ Y, BRAVO J, HERRERA-ACOSTA J, et al: Apoptosis and NF-kB activation are simultaneously induced in renal tubulointerstitium in experimental hypertension. Kidney Int 64 (Suppl 86):S27-S32, 2003
17. OCKAILI R, SALLOUM F, HAWKINS J, KUKREJA RC: Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits. Am J Physiol 283:H1263-H1269, 2002
18. KELLY DJ, ZHANG Y, GOW R, GILBERT RE: Tranasilat attenuates structural and functional aspects of renal injury in the remnant kidney model. J Am Soc Nephrol 15:2619-2629, 2004
19. KLONER RA: Novel phosphodiesterase type 5 inhibitors: Assessing hemodynamic effects and safety parameters. Clin Card 27 (Suppl 1):120-125, 2004
20. WILKENS H, GUTH A, KONIG J, et al: Effect of inhaled iloprost oral sildenafil in patients with primary pulmonary hypertension. Circulation 104:1218-1222, 2001
21. GHOFRANI H, REICHENBERG F, KOHSTANN MG, et al: Sildenafil increased excercise capacity capacity during hypoxia at low altitude and at Mount Everest. Ann Intern Med 141:169-177, 2004
22. GRIFFIN KA, PICKEN M, BIDANI A: Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 46:1010-1018, 1994
23. BIDANI AK, GRIFfiN KA, BAKRIS G, PICKEN MM: Lack of evidence of pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 57:1651-1661, 2000
24. KANG DH, NAKAGAWA T, FENG L, JOHNSON RJ: Nitric oxide modulates vascular disease in the remnant kidney model. Am J Pathol 161:239-248, 2002
25. RISDON RA, SLOPER JC, DE WARDENER HE: Relationship between renal function and histological changes found in renal biopsy specimens from patients with persistent glomerular nephritis. Lancet 2:363-366, 1968
26. SCHAINUCK LI, STRIKER GE, CUTLER RE, BENDITT EP: Structural-functional correlations in renal disease. II. The correlations. Human Pathol 1:631-641, 1970
27. MACKENSEN-HAEN S, BADER R, GRUND KE, BOHLE A: Correlations between renal cortilcal interstitial fibrosis, atrophy of proximal tubules and ipairment of glomerular filtration rate. Clin Nephrol 15:167-171, 1981
28. SUGIYAMA H, KASHIHARA N, MAKINO H, et al: Apoptosis in glomerular sclerosis. Kidney Int 49:103-111, 1996
29. DAS A, XI L, KUKREJA RC: Phosphodiesterase-inhibitor, sildenafil preconditions adult cardiac myocytes agains necrosis and apoptosis: Essential role of NO signaling. J Biol Chem 280:12944-12955, 2005
30. SINDHU RK, EHDALE A, VAZIRI ND, ROBERTS CK: Effects of chronic renal failure on caveolin-1, guanylate cyclase and AKT protein expression. Biochem Biophys Acta 1690:231-237, 2004
31. REMUZZI G, ZOJA C, GAGLIARDINI E, et al: Combining an antiproteinuric approach with mycophenolate mofetil fully suppresses progressive nephropathy of experimental animals. J Am Soc Nephrol 10:1542-1549, 1999
32. FUJIHARA CK, DE LOURDES NORONHA I, et al: Combined mycophenolate mofetil and losartan therapy arrests established injury in the remnant kidney. J Am Soc Nephrol 11:283-290, 2000
33. REMUZZI G, CHIURCHIU C, RUGGENENTI P: Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). Kidney Int (Suppl 92):S90-S96, 2004
34. HIRSCHBERG R, WANG S: Proteinuria and growth factors in the development of tubulointerstitial injury and scarring in kidney disease. Curr Opin Nephrol Hypertens 14:43-52, 2005
35. EMANUELI C, SALIS MB, VAN LINTHOUT S, et al: Akt/protein kinase B and endothelial nitric oxide synthase mediate neovascularization induced by tissue kallikrein gene transfer. Circulation 110:1638-1644, 2004
36. ZHANG JJ, BLEDSOE G, KATO K, et al: Tissue kallikrein attenuates salt-induced renal fibrosis by inhibition of oxidative stress. Kidney Int 66:722-732, 2004
37. CHAO J, CHAO L: Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 90:291-298, 2005
38. VALENTE EG, VERNET D, FERRINI MG, et al: L-arginine and hosphodiesterase (PDE) inhibitors counteract fibrosis in Peyronie's fifrotic plaque and related fibroblast cultures. Nitric Oxide 9:229-244, 2003
39. AIELLO S, NORIS M, TODESCHINI M, et al: Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 52:171-181, 1997
40. ZOJA C, BENIGNI A, CAMOZZI D, et al: Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heyman nephritis. Kidney Int 64:857-863, 2003
41. REYES AA, PUKERSON ML, KART I, KLAHR S: Dietary supplementation with L-arginine ameliorates the progression of renal disease in rats with subtotal nephrectomy. Am J Kidney Dis 20:168-176, 1992
42. ASHAB I, PEER G, BLUM M, et al: Oral administration of L-arginine and captopril in rats prevents chronic renal failure by nitric oxide production. Kidney Int 47:1515-1521, 1995
43. BENIGNI A, ZOJA C, NORIS M, et al: Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. Am J Kidney Dis 33:746-753, 1999
44. WHITE CR, BROCK TA, CHANG LY, et al: Superoxide and peroxynitrite in atherosclerosis. Proc Nat Acad Sci USA 91:1044-1048, 1994
45. BALLINGER SW, PATTERSON C, YAN CN, et al: Hydrogen peroxide and peroxynitrite-induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ Res 86:960-966, 2000
46. ESPEY MG, MIRANDA KM, THOMAS DD, et al: A chemical perspective on the interplay between NO, reactive oxygen species and reactive nitrogen species. Ann NY Acad Sci 962:195-206, 2002
47. RODRÍGUEZ-ITURBE B, VAZIRI ND, HERRERA-ACOSTA J, JOHNSON RJ: Oxidative stress, renal infiltration of immune cells and salt-sensitive hypertension: All for one and one for all. Am J Physiol Renal Physiol 286: F606-F616, 2004
48. RANGAN GK, WANG Y, HARRIS DC: Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 12:1696-1705, 2001